Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Abstracts are available and open access.
Slides and webcasts are restricted to attendees and ESMO Members.
Results from the ASTEROID study with durvalumab after stereotactic body radiotherapy in patients with early stage non-small cell lung cancer
Results from early halted PIPSeN study in chemonaïve patients with non-small cell lung cancer without EGFR or ALK/ROS alterations
Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines
Data with approximately 3 years of follow-up from the KEYNOTE-407 study show improved survival with pembrolizumab added to chemotherapy
Molecular characterisation of tumours with alterations in the PIK3 pathway
More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates
Agents with CNS activity may have improved outcomes for patients with non-small cell lung cancer and brain metastases at diagnosis
Findings from a large analysis of the GENIE Cohort v8.1
A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
